Article Versions Notes

Basso M, Battagin G, Nicolè S, Rossi MC, Colombo F, Pirola N, Baratti S, Storato S, Giovagnorio F, Malagnino V, et al. Predicting Factors of Plasma HIV RNA Undetectability after Switching to Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Experienced HIV-1 Patients: A Multicenter Study. Viruses. 2023; 15(8):1727. https://doi.org/10.3390/v15081727

Basso, Monica, Giuliana Battagin, Stefano Nicolè, Maria Cristina Rossi, Francesco Colombo, Nicole Pirola, Stefano Baratti, Silvia Storato, Federico Giovagnorio, Vincenzo Malagnino, and et al. 2023. "Predicting Factors of Plasma HIV RNA Undetectability after Switching to Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Experienced HIV-1 Patients: A Multicenter Study" Viruses 15, no. 8: 1727. https://doi.org/10.3390/v15081727

Basso, M., Battagin, G., Nicolè, S., Rossi, M. C., Colombo, F., Pirola, N., Baratti, S., Storato, S., Giovagnorio, F., Malagnino, V., Alessio, G., Vinci, A., Maurici, M., Sarmati, L., & Parisi, S. G. (2023). Predicting Factors of Plasma HIV RNA Undetectability after Switching to Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Experienced HIV-1 Patients: A Multicenter Study. Viruses, 15(8), 1727. https://doi.org/10.3390/v15081727